Recently, we identified lysine methyltransferase (KMT) 9, an obligate heterodimer consisting of KMT9α (also known as N6AMT1) and KMT9β (also known as TRMT112), as a novel target in cancer. The gene discussed is HEMK2; the disease is cancer.